Results 71 to 80 of about 21,135 (199)

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults

Journal of the International Association of Providers of AIDS Care, 2019
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015 ...
Oche O. Agbaji MBBS, Isaac O. Abah B.Pharm, MPH, Augustine O. Ebonyi MBBS, MSc, Zumnan M. Gimba MBBS, Esla E. Abene MBBS, Simji S. Gomerep MBBS, Kakjing D. Falang PhD, Joseph Anejo-Okopi PhD, Patricia A. Agaba MBBS, Placid O. Ugoagwu BSc, Emmanuel I. Agaba MBBS, Godwin E. Imade PhD, Atiene S. Sagay MBBS, Prosper Okonkwo MBBS, John A. Idoko MBBS, Phyllis J. Kanki DVM, DSc   +15 more
doaj   +1 more source

Development and validation of a stability-indicating lc method for the determination of tenofovir disoproxil fumarate in pharmaceutical formulation [PDF]

, 2012
The present study describes the degradation of tenoforvir disoproxil fumarate (teno) under different prescribed stressconditions (hydrolysis, oxidation, dry and wet heat and photolysis) following the International Conference on Harmonization and ...
Shweta Havele, Sunil R. Dhaneshwar
core  

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang, Jia‐Lan Wang, Su‐Wen Jiang, Ai‐Wu Zhou, Meng‐Han Jin, Hao‐Jin Zhang, Shi‐Qi Yang, Shi‐Yang Fan, Ai‐Rong Hu   +8 more
wiley   +1 more source

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]

, 2019
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M., Conn, Mitchell I., DiMarino, Anthony J., Hann, Hie-Won, Kroop, Howard, Martin, Aaron, Prieto, Jorge, Shinn, Brianna J.   +7 more
core   +1 more source

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. [PDF]

, 2017
Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile.
Battegay, Manuel, Bernasconi, Enos, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Gayet-Ageron, Angèle, Hirzel, Cedric, Schmid, Patrick, Sculier, Delphine, Swiss HIV Cohort Study   +9 more
core   +5 more sources

Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction HIV guidelines recommend switching from a three‐drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long‐term outcomes of adults with HIV RNA <50 copies/ml who switched to DTG+3TC or a guideline‐recommended ...
Erik Sörstedt, George Nduva, Fredrik Månsson, Åsa Mellgren, Johanna Repits, Eva Fernvik, Adam Stubbs, Melanie Schroeder, Johanna Brännström, Christina Carlander   +9 more
wiley   +1 more source

Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study

Oman Medical Journal, 2019
Objectives: Tenofovir disoproxil fumarate (TDF) has been reported to cause nephrotoxicity necessitating cessation in some patients. No information is available on the nephrotoxic effect of TDF in Omani or regional patients with HIV infection.
Kowthar Salman Hassan, Abdullah Balkhair
doaj   +1 more source

Overcoming barriers, driving progress: Clinical science at IAS 2025

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction The 13th IAS Conference on HIV Science, held in Kigali, Rwanda (13–17 July 2025), highlighted key advances in clinical research. Presentations focused on sustaining HIV treatment and prevention amid financial constraints, innovations in long‐acting oral antiretrovirals, and the management of comorbidities and co‐infections ...
Ezequiel Cordova, Simiso Sokhela, Jasmini Alagaratnam, Juan Ambrosioni   +3 more
wiley   +1 more source

Improved central nervous system symptoms in people with HIV without objective neuropsychiatric complaints switching from Efavirenz to Rilpivirine containing cART [PDF]

, 2019
Objective: Occult central nervous system (CNS) symptoms not recognized by people living with HIV (PLWH) receiving efavirenz or their clinicians could occur and impact people’s quality of life. The aim of this study was to determine whether CNS parameters
Alagaratnam, Jasmini, Boffito, Marta, Bracchi, Margherita, Fox, Julie, Lwanga, Julianne, Nelson, Mark, Vera Rojas, Jaime H, Winston, Alan   +7 more
core   +1 more source